维多利亚老品牌76696vic-在线入口

HANLIKANG

Rituximab Injection

HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator rituximab has not been approved in China, benefiting a wider patient population with differentiated strategies.

Drug Instruction

HANQUYOU（trade name: HERCESSI™ in the U.S., Zercepac^® in Europe）

Trastuzumab

HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe) was successfully launched in the U.S., China and Europe, becoming the Chinese mAb biosimilar entering the U.S., the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator and brings more treatment options to patients with HER2 positive breast and gastric cancer worldwide.

Drug Instruction

HANDAYUAN

Adalimumab Injection

The Company's first product indicated for the treatment of autoimmune diseases. HANDAYUAN (adalimumab injection) was approved by the NMPA in December 2020. It is indicated for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease and pediatric Crohn’s disease.

Drug Instruction

HANBEITAI

Bevacizumab Injection

HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Proposed to be combined with HANSIZHUANG (PD-1) for immuno-oncology combination therapies to treat various tumors.

Drug Instruction

HANSIZHUANG

Serplulimab Injection

HANSIZHUANG (serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was launched in March 2022. It has been approved by the NMPA for the treatment of microsatellite instability-high (MSI-H) solid tumours, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and innovative therapies, and has initiated many clinical trials on immuno-oncology combination therapies worldwide, covering a wide range of indications, such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma and gastric cancer, etc.

Drug Instruction

HANNAIJIA

Neratinib

HANNAIJIA (neratinib), an orally administered small-molecule pan-HER tyrosine kinase inhibitor (TKI), was approved by NMPA in June 2024, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. It can be used as sequential therapy after completion of HANQUYOU (trastuzumab) that is self-developed by the company to further reduce the risk of recurrence for patients with early-stage HER2-positive breast cancer.

Drug Instruction